We are pleased that Glass Lewis agrees that changing the Amarin Board is not warranted. Sarissas
campaign is nothing more than a transparent attempt to de facto gain control of the Amarin Board by removing our new Chairman and installing seven underqualified individuals. Sarissa has failed to present a single actionable or new idea, and Glass
Lewis has recognized that its slate of nominees is not only underqualified but represents significant risk at a critical juncture in Amarins transformation. Throughout this unnecessary and costly proxy contest, Sarissa has demonstrated just
one thing: that it has absolutely no understanding of Amarins business or the markets in which we operate.
At a time when Amarin needs to be laser
focused on execution, nearly doubling the size of the Board with underqualified individuals will impede progress and be detrimental to shareholder value. We strongly urge shareholders to follow Glass Lewis recommendation and
vote AGAINST Sarissas harmful resolutions on the WHITE proxy card today.
Amarin reminds
shareholders that every vote is important, no matter how many or few shares it represents. Shareholders are urged to discard any blue proxy materials and to only vote using the WHITE proxy card. Shareholders can switch their
vote at any time by simply voting on the WHITE proxy card AGAINST all of Sarissas harmful proposals. Only the latest-dated proxy counts.
Amarin shareholders of record as of January 23, 2023, are entitled to vote at the General Meeting.
Amarin shareholders who need assistance in voting their shares may call Amarins proxy solicitors, Morrow Sodali at (800)
662-5200 (toll-free) or (203) 658-9400 (collect) or Okapi Partners at (844) 343-2625 (toll-free) or (212) 297-0720 (international).
Additional materials regarding the Board of Directors recommendations for the General
Meeting can be found at www.voteamarin.com.
Advisors
J.P. Morgan is acting as financial advisor. Ropes & Gray LLP and Goodwin Procter LLP are acting as legal advisors to the Company.
About Amarin
Amarin is an innovative pharmaceutical
company leading a new paradigm in cardiovascular disease management. From our foundation in scientific research to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin has offices in
Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. We are committed to increasing the scientific understanding of the
cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk.
Forward-Looking Statements
This press release contains forward-looking statements which are made pursuant to U.S. federal securities law. These forward-looking statements are not
promises or guarantees and involve substantial risks and uncertainties. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarins filings with the U.S.
Securities and Exchange Commission, including Amarins annual report on Form 10-K for the full year ended 2021, and